Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 9649
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yokoi, K. Articles by Abbruzzese, J. L. Search for Related Content PubMed Articles by Yokoi, K. Articles by Abbruzzese, J. L.

Abstract

Serum Amyloid A (SAA) in Patients with Pancreatic Carcinoma

U Texas M. D. Anderson Cancer Center, Houston, TX

9649

Background: New biomarkers are essential for the diagnosis and monitoring of human pancreatic carcinoma. In our previous study, sera collected from nude mice implanted in the pancreas with human pancreatic cancer cells were analyzed by Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry. The progressive growth of the tumors directly correlated with the level of Serum Amyloid A (SAA). In the present study, we determined whether plasma levels of SAA correlated with the stage of pancreatic carcinoma in patients. Methods: Plasma was collected from 113 normal volunteers and 134 patients with pathologically confirmed pancreatic adenocarcinoma. The plasma level of SAA was determined by enzyme linked immunosorbent assay (ELISA). Results: The concentration of SAA in plasma of pancreatic cancer patients was significantly higher than that in normal volunteers (mean value: 180.1 vs 27.9 mg/L; P<0.01), and had a tendency to increase in later stages of the disease. Specifically, the level of SAA in stage IV B patients was significantly higher than that in stage I patients and normal volunteers (282.9 vs 17.8 and 27.9 mg/L; P<0.01). Immunohistochemical analysis of pancreatic tumor specimen revealed intense expression of SAA in the malignat epithelium of the carcinomas with less intense staining of desmoplastic fibroblasts. Conclusions: SAA may be a useful biomarker for monitoring of patients with advanced pancreatic cancer.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech; Novartis Pharma